22May 2023
Interim Results of a Phase 1/2 Open‐Label Study of INO‐3107 for HPV‐6 and/or HPV‐11‐Associated Recurrent Respiratory Papillomatosis

Interim Results of a Phase 1/2 Open‐Label Study of INO‐3107 for HPV‐6 and/or HPV‐11‐Associated Recurrent Respiratory Papillomatosis

This study evaluates the safety, immunogenicity, and efficacy of INO‐3107, a DNA immunotherapy designed to elicit targeted T‐cell responses against human papillomavirus (HPV) types 6 and 11 in adult patients with recurrent respiratory papillomatosis. An initial cohort of 21 patients was enrolled. The most frequently reported TEAE was injection site or procedural pain (n = 8; 38.1%). Sixteen (76.2%) patients had fewer surgical interventions in the year following INO‐3107 administration, with a median decrease of 3 interventions versus the preceding year. The data suggest that INO‐3107 administered by IM/EP is tolerable and immunogenic and provides clinical benefit to adults with RRP.

  • #ent

Like

Save

Share